STOCK TITAN

SenesTech, Inc. Announces Closing of $10 Million Private Placement Priced At-the-Market

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

SenesTech, Inc. (NASDAQ: SNES) has successfully closed a private placement of 4,388,854 shares of common stock and related warrants, generating approximately $10 million in gross proceeds. The shares were sold at $2.2785 each, with warrants priced at $2.216 per share. The funds raised will be allocated for general corporate purposes. The offering was conducted without a public offering and the securities have not been registered under the Securities Act, requiring an initial registration statement to be filed for resale.

Positive
  • Raised approximately $10 million in gross proceeds.
  • Successful private placement indicates investor confidence.
Negative
  • Securities sold are not registered under the Securities Act, limiting resale options.

PHOENIX, Feb. 2, 2021 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary, next generation technologies for managing animal pest populations through fertility control, today announced the closing of its previously announced private placement of 4,388,854 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 2,194,427 shares of common stock, at a purchase price of $2.2785 per share of common stock (or common stock equivalent in lieu thereof) and associated warrant in a private placement priced at-the-market under Nasdaq rules and resulted in gross proceeds of approximately $10 million before the deduction of placement agent fees and expenses and estimated offering expenses payable by the Company.

H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering.

The warrants have an exercise price of $2.216 per share, are exercisable immediately and have a term of five and one-half years.

The Company intends to use the net proceeds for general corporate purposes.

The offer and sale of the foregoing securities were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

Under an agreement with the investors, the Company is required to file an initial registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock to be issued to the investors.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

About SenesTech

SenesTech is changing the model for pest management by targeting one of the root causes of the problem: reproduction.

ContraPest® is an innovative technology with an approach that targets the reproductive capabilities of both sexes in rat populations, inducing egg loss in female rats and impairing sperm development in males. Using a proprietary bait delivery method, ContraPest® is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rat communities. ContraPest® is designed, formulated and dispensed to be low hazard for handlers and non-target species such as wildlife, livestock and pets, where the active ingredients break down rapidly.

We believe ContraPest® will establish a new paradigm in rodent control, resulting in a decreased reliance on lethal options. For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement

The foregoing paragraphs contain forward-looking statements that involve estimates, assumptions, risks and uncertainties. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. "Forward-looking statements" may be preceded by words such as "may," "future," "plan" or "planned," "will," "should," "expected," "anticipates," "continue," "eventually," "believes," or "projected." Forward-looking statements include statements concerning the anticipated use of the proceeds of the private placement and the Company's commercialization of its technology.

Investors should not unduly rely on forward-looking statements. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those made in the forward-looking statements, including as a result of various factors and other risks, such as market conditions, satisfaction of closing conditions, and other factors identified in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K and quarterly reports filed on Form 10-Q. All forward-looking statements speak only as of the date on which they were made based on management's assumptions as of such date. The Company does not undertake any obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.

CONTACT:

Investors: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC,
602-889-9700, senestech@lythampartners.com

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc.,
928-779-4143

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/senestech-inc-announces-closing-of-10-million-private-placement-priced-at-the-market-301220594.html

SOURCE SenesTech, Inc.

FAQ

What was the amount raised by SenesTech in the recent private placement?

SenesTech raised approximately $10 million in gross proceeds from the private placement.

What is the purchase price per share for SenesTech's private placement?

The shares were sold at a purchase price of $2.2785 per share.

What is the exercise price of the warrants issued in SenesTech's private placement?

The exercise price of the warrants is $2.216 per share.

How many shares were included in SenesTech's recent private placement?

A total of 4,388,854 shares of common stock were included in the private placement.

What will SenesTech use the proceeds from the private placement for?

The net proceeds from the private placement will be used for general corporate purposes.

SenesTech, Inc.

NASDAQ:SNES

SNES Rankings

SNES Latest News

SNES Stock Data

2.32M
1.03M
0.02%
1.89%
4.64%
Specialty Chemicals
Agricultural Chemicals
Link
United States of America
PHOENIX